AIM
ALXN

Acrospire Investment Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Acrospire Investment Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-800
Closed -$97K – 1731
2017
Q2 		$97K Sell
800
-500
-38% -$58.2K 0.09% 271
2017
Q1 		$158K Sell
1,300
-1,100
-46% -$142K 0.13% 103
2016
Q4 		$294K Buy
2,400
+1,200
+100% +$147K 0.12% 159
2016
Q3 		$147K Buy
1,200
+400
+50% +$51.5K 0.1% 286
2016
Q2 		$93K Buy
800
+300
+60% +$42.6K 0.07% 525
2016
Q1 		$70K Buy
+500
New +$73.4K 0.05% 632

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Acrospire Investment Management's ALXN Position: Q3 2017 in Review

Acrospire Investment Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2017, closing a stake of 800 shares — an estimated $97K sold.

Acrospire Investment Management first reported a position in ALXN in Q1 2016 and held it in 6 quarters. The position peaked at $294K in Q4 2016. 595 funds tracked by Wall St. Rank hold ALXN as of Q3 2017.

  • Acrospire Investment Management reported no remaining Alexion Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 800 Alexion Pharmaceuticals shares in Q3 2017, an estimated $97K.
  • Acrospire Investment Management first reported a position in Alexion Pharmaceuticals in Q1 2016 and held it in 6 quarters.
  • Acrospire Investment Management's Alexion Pharmaceuticals position peaked at $294K in Q4 2016.
  • 595 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.